Primary Sclerosing Cholangitis Epidemiology Forecast to 2030 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Primary Sclerosing Cholangitis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Primary Sclerosing Cholangitis - Epidemiology Forecast to 2030 delivers an in-depth understanding of the disease, historical, and forecasted Primary Sclerosing Cholangitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Primary Sclerosing Cholangitis: Understanding

The Primary Sclerosing Cholangitis epidemiology report gives a thorough understanding of the Primary Sclerosing Cholangitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Primary Sclerosing Cholangitis in the US and Europe. Moreover, the report covers the detailed information of the Primary Sclerosing Cholangitis epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective

This section encompassing Primary Sclerosing Cholangitis epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Primary Sclerosing Cholangitis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

KOL Views

The publisher interviews KOLs and includes SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Report Highlights

• 11-year Forecast of Primary Sclerosing Cholangitis Epidemiology
• 7MM Coverage
• Prevalent cases of Primary Sclerosing Cholangitis
• Prevalence of Primary Sclerosing Cholangitis by gender
• Comorbidities associated with Primary Sclerosing Cholangitis

Key Topics Covered:

1 Key Insights

2 Executive Summary of Primary Sclerosing Cholangitis

3 SWOT Analysis for Primary Sclerosing Cholangitis

4 Primary Sclerosing Cholangitis Market Overview at a Glance

4.1 Market Share (%) Distribution of PSC in 2017

4.2 Market Share (%) Distribution of PSC in 2030

5 Disease Background and Overview

5.1 Introduction

5.2 Etiology

5.3 Signs and Symptoms

5.4 Risk Factors and genetics

5.5 Clinical Phenotypes

5.6 Pathophysiology

5.6.1 Immunopathology of PSC

5.7 Associated Diseases and Complications

5.8 Clinical Presentation

5.9 Diagnostic Investigations

5.10 Cancer Surveillance in PSC

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Prevalent Population of Primary Sclerosing Cholangitis in 7MM

6.3 Assumption and Rationale: 7MM

7 Country-wise Epidemiology of Primary Sclerosing Cholangitis

7.1 The United States

7.1.1 Prevalent cases of Primary Sclerosing Cholangitis in the United States

7.1.2 Prevalence of Primary Sclerosing Cholangitis by Gender in the United States

7.1.3 Comorbidities associated with Primary Sclerosing Cholangitis in the United States

7.2 Germany

7.3 France

7.4 Italy

7.5 Spain

7.6 The United Kingdom

7.7 Japan

8 Treatment and Management

8.1 Guidelines

8.1.1 American College of Gastroenterology Guidelines

8.1.2 AASLD Guidelines for treatment and management of PSC

8.1.3 British Society of Gastroenterology and UK-PSC guidelines for the Diagnosis and Management of primary sclerosing cholangitis

8.2 Patient Journey

8.3 Case study

8.3.1 Primary Sclerosing Cholangitis: As case Discussion in the US

9 Unmet Needs

10 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/f6ptzd